Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective, randomized, double-blind comparison of LY2963016 versus Lantus in type 2 diabetes mellitus
2011-000828-15Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in hemoglobin A1c from baseline to 24 weeks. Started Jun 2011; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-000828-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000828-15.